Nivolumab is an ICI that blocks the interaction between programmed cell death protein-1 (PD‐1) expressed on T cells and its ligands programmed cell death protein ligand-1 (PD‐L1) and PD‐L2, expressed on antigen‐presenting cells and cancer cells [12, 13]. This evidence concerns the gene PDCD1 and cancer.